News Focus
News Focus
icon url

DewDiligence

02/13/14 2:06 PM

#174176 RE: jbog #174175

ENTA’s $195M of regulatory milestones payments from ABBV are more than merely potential sources of cash. At this point, no serious investors can think that ABBV/ENTA’s 3-DAA regimen won’t be approved for marketing within the next year or so.